Zacks Investment Research Upgrades Supernus Pharmaceuticals Inc. (SUPN) to Buy
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The brokerage currently has a $26.00 price target on the specialty pharmaceutical company’s stock. Zacks Investment Research’s price objective suggests a potential upside of 9.06% from the stock’s current price.
According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
A number of other brokerages also recently commented on SUPN. Piper Jaffray Cos. downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a research note on Monday, July 18th. Jefferies Group restated a “buy” rating and issued a $28.00 target price (up previously from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Finally, Northland Securities downgraded Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research note on Monday, July 18th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $25.25.
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 23.84 on Wednesday. Supernus Pharmaceuticals has a 52 week low of $9.51 and a 52 week high of $26.84. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of 48.65 and a beta of 1.73. The firm’s 50-day moving average price is $23.47 and its 200-day moving average price is $19.98.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.05. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The firm had revenue of $50.40 million for the quarter, compared to the consensus estimate of $49.67 million. During the same quarter in the previous year, the company posted $0.03 earnings per share. The business’s quarterly revenue was up 43.6% compared to the same quarter last year. Equities research analysts expect that Supernus Pharmaceuticals will post $0.68 EPS for the current fiscal year.
In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the business’s stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the sale, the chief financial officer now owns 3,616 shares of the company’s stock, valued at $90,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.10% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the company. Fiera Capital Corp bought a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $27,544,000. Loomis Sayles & Co. L P boosted its stake in shares of Supernus Pharmaceuticals by 96,990.1% in the second quarter. Loomis Sayles & Co. L P now owns 763,128 shares of the specialty pharmaceutical company’s stock worth $15,545,000 after buying an additional 762,342 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $14,610,000. Bellevue Group AG bought a new stake in shares of Supernus Pharmaceuticals during the first quarter worth $6,725,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Supernus Pharmaceuticals by 34.3% in the second quarter. Bank of New York Mellon Corp now owns 1,659,604 shares of the specialty pharmaceutical company’s stock worth $33,806,000 after buying an additional 423,835 shares in the last quarter. 94.66% of the stock is owned by institutional investors.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.